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ABSTRACT 
BACKGROUND 
Many patients present to the surgical department with a 
thyroid nodule. However not all require surgery and only 5-6% of 
these are malignant. There are many methods to diagnose and 
predict malignancy in a thyroid nodule. This study throws light on 
the usefulness of clinical, radiological and TSH estimation and its 
role in predicting malignancy. 
AIMS AND OBJECTIVES 
To assess whether simple clinical, radiological and 
biochemical parameters that can predict the likelihood of thyroid 
malignancy in subjects with thyroid swelling , in a tertiary care 
centre in south India, which caters mostly for an economically 
underprivileged population  
MATERIAL AND METHODS 
This prospective study involved 100 patients admitted to 
MMC, Chennai with thyroid swellings. A descriptive analysis of 
clinical presentation, radiological features and a correlation of TSH 
level and its final histopathology were done. 
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OBSERVATION AND RESULTS 
Most patients were females. Most of the malignancy patients fall in 
the age group above 60. Commonest presentation was a rapidly growing 
thyroid swelling of short duration or development of secondary 
symptoms in a long standing goitre. Majority of patients presented with a 
SNT. The incidence of malignancy was higher in SNT compared to 
MNG. The incidence of neck nodes was more common malignancy 
patients. Most of the malignancy patients have radiological features such 
as hypoechoic lesion, calcification, irregular margins and invasion to 
adjacent structures .Mean preoperative TSH value in malignancy was 
higher compared to those with benign disease. Incidence of malignancy 
increased with higher TSH values. 
CONCLUSION 
There is a definite relationship between higher TSH levels and 
malignancy. TSH levels could be used as predictor in clinically 
suspicious malignant thyroid swelling with a benign FNAC report. In 
such cases where TSH value is high, the FNAC can be relooked to 
confirm the diagnosis. In addition to TSH, clinical features such as 
lymphadenopathy, fixity, SNT, USG features such as hypoechoic, 
calcification, invasion to adjacent structures are also predictors of thyroid 
malignancy. 
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INTRODUCTION 
Thyroid diseases have always been an enigma. The 
management of thyroid diseases has undergone a tremendous 
change over the ages, from the crude surgeries of the ancient 
times to the multidisciplinary approach of the modern era. 
However in the present scenario surgery still plays an important 
role especially in the management of thyroid malignancies. 
Thyroid malignancies account for 90% of endocrinal 
malignancies. The incidence of thyroid malignancies has 
increased three fold over the past 3 decades. Many patients 
present to the surgical outpatient department with a thyroid 
nodule. However not all these patients require surgery as only 5-
6% of these are malignant [26, 27]. There are many methods to 
diagnose and predict malignancy in a thyroid nodule. 
A clinical examination is always the first step to assess a 
nodule. A thyroid profile is also essential. This is accompanied 
by certain tests which increase the rate of detection. Fine needle 
aspiration cytology (FNAC) is the present gold standard and 
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primary tool for assessing risk of malignancy [1]. Other tests 
include ultrasonography, thyroid scintigraphy, CT scan and MRI. 
Recent studies have found levels of serum TSH to be an 
independent predictor of malignancy in thyroid nodules [2, 3, 
5].This biochemical marker could be used as a screening test for 
malignancy. In this study we investigated the utility of TSH in 
predicting malignancy and the common clinical presentation of 
thyroid malignancies. 
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AIMS AND OBJECTIVES 
Although fine-needle aspiration cytology is considered to be 
the reference method for evaluating thyroid nodules, the results are 
inaccurate in approximately 10-30% of cases. Several studies have 
attempted to predict the risk of malignancy in thyroid nodules 
based on age, nodularity, thyrotropin values, thyroid autoimmune 
disease, hot/cold nodule status, and ultrasound parameters. 
However, no consensus has been found, and none of these 
parameters has significantly affected patient management. The 
management of indeterminate thyroid nodules and re-biopsies of 
nodules with initially benign cytological results remain important 
and controversial topics of discussion.In this study the usefulness 
of clinical,radiological and biochemical factors in predicting the 
thyroid malignancy is discussed. 
The main objective of this study is 
1) To evaluate the utility of serum TSH estimation as a 
biochemical predictor of malignancy in suspicious thyroid 
nodules. 
2) To study the clinical features, radiological findings that 
can predict the various thyroid malignancies. 
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REVIEW OF LITERATURE 
HISTORY [6, 7, 8]: 
The history of thyroid diseases can be traced back to ancient 
times. Celsus and Galen described goiters (Latin: guttur=throat) 
in 1st century A.D. 
Thomas Wharton (1656) coined the term thyroid gland 
(Greek: thyreoeides =shield) because of its appearance as a shield 
protecting the trachea. 
Andrea Vesalius (1514–1564) originally described the 
thyroid as ―glandulae laryngis‖ in his inauguration of modern 
anatomy De Humani Corporis Fabrica. 
Lorenz Heister of Germany first described the surgical 
removal of a thyroid gland. 
Aniton Wölfler first called attention to the danger of 
injuring the recurrent nerve when ligating the inferior thyroid 
artery. 
Theodor Billroth (1892-1894) and Theodor Kocher (1849-
1917) were eminent surgeons who performed thyroid surgeries 
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in the 19th century. Kocher was awarded the Nobel Prize in 1909 
for his work on thyroid physiology, pathology and surgery. 
Ivar Sandström (1887) of Sweden discovered parathyroids 
and described the anatomy and blood supply of the glands. 
C. H. Mayo of USA had tremendous experience in thyroid 
surgery. Reports from the Mayo Clinic had been an important 
factor in disseminating an understanding of the surgical  
technique and operative difficulties, which, in turn, greatly 
improved thyroid surgery. 
William Halstead (1852-1922) of USA stressed the 
importance of preservation of parathyroids during thyroid 
surgery. 
Saul Hertz (1905–1950) was an American physician who 
discovered the use of radioactive iodine for the treatment of 
thyroid diseases. 
Martin and Ellis (1930) first described FNAC of thyroid. 
Duffy et al (1950) studied relationship of papillary 
carcinoma of thyroid and neck irradiation in childhood. 
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Medullary thyroid carcinoma was recognized in the 1950s by 
Hazard et al. 
Sipple (1960) observed that medullary carcinoma thyroid 
was associated with pheochromocytoma. 
Development in molecular medicine in the 1980s has 
provided major insight into the impact of genetic mutations 
eventually to thyroid carcinomas. This led to the recognition of 
the biologically different behavior of different cancer subtypes 
and to the introduction of differentiated surgical strategies. 
EMBRYOLOGY: [6, 9] 
The thyroid gland appears as an epithelial proliferation in 
the floor of the pharynx near the base of the tongue at a point 
later indicated by the foramen caecum. Subsequently  the  
thyroid  descends  in  front  of  the  pharyngeal  gut  as  a  
bilobed diverticulum. During this migration, the thyroid remains 
connected to the tongue by a narrow canal, the thyroglossal duct. 
This duct usually disappears by the 6th week. The thyroid gland 
descends in front of the hyoid bone and the laryngeal cartilages 
and reaches its final position in front of the trachea in the 
 7 
seventh week. By then it has acquired a small median isthmus and 
two lateral lobes. 
The thyroid begins to function at approximately the end of 
the third month, at which time the first follicles containing colloid 
become visible. 
The remnant of the thyroglossal duct may persist as a 
thyroglossal cyst which may lie at any point along the migratory 
path of the thyroid. Sometimes it may be connected to the 
outside by a fistulous track called thyroglossal fistula. 
Aberrant thyroid tissue may be found anywhere along the 
path of descent of the thyroid gland and is subject to the same 
diseases as the thyroid gland itself. 
Calcitonin-producing C cells or the parafollicular cells arise 
from the ultimobranchial body. These cells are of 
neuroectodermal origin migrate into the lateral and posterior 
upper two thirds of the thyroid lobes and are distributed among the 
follicles. 
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ANATOMY [10]: 
The thyroid gland consists typically of two lobes, a 
connecting isthmus, and occasionally an ascending pyramidal 
lobe. 
It extends from 5th cervical vertebra to 1st thoracic 
vertebra with the isthmus overlying the second and third tracheal 
ring. 
The gland weighs approximately 25-30g 
CAPSULES 
True capsule: From condensation of connective tissue of 
the gland. False capsule: External to the true capsule, is well 
developed and derived from the pretracheal fascia. Anteriorly and 
laterally this fascia is well developed. Posteriorly it is thin and 
loose, permitting enlargement of the gland posteriorly. The false 
capsule, or fascia, is not removed with the gland during 
thyroidectomy. 
Ligament of berry: This is a thickening of the fascia that 
fixes the back of each lobe to the cricoid cartilage. Such 
thickenings are the ligaments of Berry. 
 9 
 
PARATHYROID GLANDS 
The superior parathyroid glands normally lie between the 
true capsule and the fascial false capsule. The position of the 
inferior parathyroid is more variable, however, and can be along 
the branches of the inferior thyroid vein lateral or inferior to the 
lowermost portion of the thyroid lobe. The superior and inferior 
parathyroid glands have a single end artery that supplies them 
medially from the inferior thyroid artery. 
VASCULAR SUPPLY 
ARTERIES 
The thyroid gland derives its blood supply from the 
external carotid system via the superior thyroid artery and the 
subclavian system via inferior thyroid artery. Sometimes there 
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may be and an additional artery the thyroid ima artery arising 
from brachiocephalic artery. 
THE SUPERIOR THYROID ARTERY 
This artery is the first branch of the external carotid artery. 
It passes downward and anteriorly to reach the superior pole of 
the gland. It usually divides into two branches at the superior 
pole: anterior and posterior. The anterior branch anastomoses 
with the contra lateral artery over the isthmus. The posterior 
branch anastomoses with branches of the inferior thyroid artery at 
the posterior border. 
INFERIOR THYROID ARTERY 
The inferior thyroid artery usually arises from the 
thyrocervical trunk. The artery divides into two or more 
branches as it crosses the ascending recurrent laryngeal nerve  
The recurrent laryngeal nerve may pass anterior or posterior 
to the artery, or between its branches 
THYROID IMA ARTERY 
The artery is unpaired and inconstant. It arises from the 
brachiocephalic artery, the right common carotid artery, or the 
aortic arch. It occurs in about 10 percent of individuals. 
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VENOUS DRAINAGE: 
Veins of the gland form a plexus of vessels lying in the 
substance and on the surface of the gland. The plexus is drained 
by three pairs of veins, the superior, middle, and inferior  thyroid 
veins. 
Superior Thyroid vein emerges at upper pole & 
accompanies the artery and ends in the Internal Jugular vein. 
Middle Thyroid vein leaves the middle of gland and has a 
short course directly into the Internal Jugular vein. It is the first 
vessel encountered in thyroidectomy 
Inferior thyroid Vein. It is the largest and most variable of 
the thyroid veins; the right and left sides are usually asymmetric. 
The veins drain into the brachiocephalic veins. 
Fourth thyroid vein [Kocher]: may emerge between the 
Middle and Inferior veins. It drains into Internal Jugular vein. 
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LYMPHATIC DRAINAGE 
The thyroid gland has an extensive intraglandular network 
of lymphatic channels that allow for drainage within one lobe 
and from one lobe to another. The lymphatic drainage can be 
divided into 4 zones (Hollinshead) 
MEDIAN SUPERIOR DRAINAGE 
From the superior margin of the isthmus and from the 
medial margins of the lateral lobes. Drains primarily into the 
digastric lymph nodes and into one or more prelaryngeal 
("Delphian") nodes just above the isthmus. Secondary drainage 
may be to upper jugular nodes on either side or to pretracheal 
nodes below the thyroid. 
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MEDIAN INFERIOR DRAINAGE 
Lymphatics draining the lower part of the isthmus and the 
lower medial portions of the lateral lobes. They  end in the 
pretracheal and brachiocephalic nodes. 
RIGHT AND LEFT LATERAL DRAINAGE 
Superiorly follow superior thyroid artery and vein. 
Inferiorly they follow the inferior thyroid artery.  
POSTERIOR DRAINAGE 
Drains into nodes along the recurrent laryngeal nerve or 
retropharyngeal nodes. 
The thyroid lymphatics typically drain first into the central 
compartment (level VI), which contains the pretracheal and 
paratracheal nodes, and subsequently into the lateral jugular 
regions (level II–IV). 
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NERVE SUPPLY 
Sympathetic system from the superior, middle, and inferior 
ganglia of the cervical chain. 
Important Relations of Thyroid 
External laryngeal nerve (ELN): 
It is a branch of the Superior laryngeal nerve of Vagus. It 
lies in lose relation with the superior vascular pedicle. It 
innervates the Cricothyroid muscle. 
RECURRENT LARYNGEAL NERVE (RLN) 
Embryonically related to 4th aortic arch  vessels 
 15 
On the right side the RLN crosses anterior to the right 
subclavian artery loops around the subclavian artery from 
posterior to anterior, crosses behind the right common carotid 
and ascends in or near the tracheoesophageal groove. It passes 
posterior to the right lobe of the thyroid gland to enter the larynx 
behind the cricothyroid articulation and the inferior cornu of the 
thyroid cartilage 
On the left side the RLN crosses the aortic arch, just distal 
to the origin of the left subclavian artery from the aortic arch. It 
loops under the ligamentum arteriosum and the aorta, and 
ascends in the same manner as the right nerve. Both nerves cross 
the inferior thyroid arteries near the lower border of the middle 
third of the gland. 
RLN enters the larynx behind the cricothyroid muscle and 
the inferior cornu of the thyroid cartilage and innervates all the 
intrinsic laryngeal muscles except the cricothyroid. 
HISTOLOGY 
The thyroid gland is divided into lobules. Each lobule 
contains 20 to 40 follicles. Each follicle is lined by cuboidal 
epithelial cells and contains a central store of colloid secreted 
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from the epithelial cells under the influence of the pituitary 
hormone, TSH. There is another group of cells in the 
interfollicular tissue called C cells or the parafollicular  cells 
which produce the hormone calcitonin. 
PHYSIOLOGY [11, 12] 
The normal thyroid gland secretes three hormones—
triiodothyronine (T3) and tetraiodothyronine (T4, thyroxine) 
from the follicular cells—to normalize growth and development, 
body temperature, and energy levels. Calcitonin, the second type 
of hormone produced by the parafollicular cell, is important in the 
regulation of calcium metabolism. 
THYROID HORMONE SYNTHESIS, SECRETION, AND 
TRANSPORT 
Iodine in diet is converted to iodides. These iodides are 
utilized by the thyroid gland to synthesize thyroid hormones. 
Thyroglobulin is a glycoprotein synthesized in the thyroid cells 
and secreted into the colloid by exocytosis of granule. It 
contains 123 tyrosine residues, but only 4 to 8 of these are 
normally incorporated into thyroid hormones. 
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STEPS OF HORMONE SYNTHESIS 
IODIDE TRAPPING 
Involves active (ATP-dependent) transport of iodide across 
the basement membrane of the thyrocyte. 
OXIDATION 
Oxidation of iodide to iodine and iodination of tyrosine 
residues on thyroglobulin (TG), to form monoiodotyrosines 
(MIT) and diiodotyrosines (DIT). Both processes are catalyzed 
by thyroid peroxidase (TPO). 
COUPLING 
The third step leads to coupling of two DIT molecules to 
form tetra-iodothyronine or thyroxine (T4 ), and one DIT 
molecule with one MIT molecule to form 3,5,3'- triiodothyronine 
(T3) or 3,3',5'–triiodothyronine reverse (rT3). When stimulated 
by TSH, thyrocytes form pseudopodia, which encircle portions 
of cell membrane containing Tg, which in turn, fuse with enzyme-
containing lysosomes. 
HYDROLYSIS 
Hydrolysis of thyroglobulin to release free iodothyronines 
(T3 and T4) and mono- and diiodotyrosines. 
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In the euthyroid state, T4 is produced and released entirely 
by the thyroid gland, whereas only 20% of the total T3 is 
produced by the thyroid. Most of the T3 is produced by 
peripheral deiodination of T4 in the liver, muscles, kidney, and 
anterior pituitary, a reaction that is catalyzed by 5'-mono-
deiodinase. Some T4 is converted to rT3, the metabolically 
inactive compound, by deiodination of the inner ring of T4. 
Thyroid hormones are transported in serum bound to 
carrier proteins such as T4- binding globulin, T4-binding 
prealbumin, and albumin. Only a small fraction (0.02%) of 
thyroid hormone (T3 and T4) is free (unbound) and is the 
physiologically active component. T3 is the more potent of the 
two thyroid hormones, although its circulating plasma level is 
much lower than that of T4. T3 is less tightly bound to protein in 
the plasma than T4, and so it enters tissues more readily. T3 is 
three to four times more active than T4 per unit weight, with a 
half-life of about 1 day, compared to approximately 7 days for T4. 
REGULATION OF THYROID HORMONES 
Thyroid hormone secretion is controlled by the 
Hypothalamic-Pituitary-Thyroid axis. The hypothalamus 
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produces a peptide, the thyrotropin-releasing hormone (TRH), 
which stimulates the pituitary to release TSH or thyrotropin. 
TRH reaches the pituitary via the portovenous circulation. 
THYROID STIMULATING HORMONE (TSH) 
Thyroid function is regulated primarily by variations in the 
circulating level of pituitary TSH. TSH secretion is increased by 
the hypothalamic hormone thyrotropin- releasing hormone (TRH) 
and inhibited in a negative feedback fashion by circulating free 
T4 and T3. TSH secretion is also inhibited by stress, and in 
experimental animals it is increased by cold and decreased by 
warmth. 
CHEMISTRY & METABOLISM OF TSH 
Human TSH is a glycoprotein that contains 211 amino acid 
residues. It is made up of two subunits, designated α and β. The α 
subunit is encoded by a gene on chromosome 6 and the β subunit 
by a gene on chromosome 1. 
TSH-α is identical to the α subunit of LH, FSH, and HCG-
α. The functional specificity of TSH is conferred by the β subunit 
The biologic half-life of human TSH is about 60 min. TSH 
is degraded for the most part in the kidneys and to a lesser extent 
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in the liver. Secretion is pulsatile, and mean output peaks at 
midnight, and then declines during the day. The normal secretion 
rate is about 110µg/d. The average plasma level is about 2 µg/mL. 
EFFECTS OF TSH ON THE THYROID 
TSH is a trophic hormone. When the pituitary is removed, 
thyroid function is depressed and the gland atrophies. TSH 
increases iodide trapping, synthesis of T3, T4, and iodotyrosines; 
secretion of thyroglobulin into the colloid; and endocytosis of 
colloid. It also increases vascularity and cellularity of the gland. 
Whenever TSH stimulation is prolonged, the thyroid becomes 
detectably enlarged. 
TSH RECEPTORS 
The TSH receptor is a typical G protein-coupled, seven-
transmembrane segment receptor that activates adenylyl cyclase 
through Gs. It also activates phospholipase C. The thyroid gland 
also is capable of autoregulation, which allows it to modify its 
function independent of TSH. As an adaptation to low iodide 
intake, the gland preferentially synthesizes T3 rather than T4, 
thereby increasing the efficiency of secreted hormone. In 
situations of iodine excess, iodide transport, peroxide 
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generation, and synthesis and secretion of thyroid hormones is 
inhibited. 
Wolff-Chaikoff effect: Excessively large doses of iodide 
may lead to initial increased organification followed by 
suppression. 
THYROID MALIGNANCIES [6, 13, 14] 
It is the most common endocrine malignancy i.e. 94.5% of 
total new endocrine cases accounting for 66% of all endocrine 
carcinoma related deaths. 
Majority of thyroid cancers presents as thyroid nodules. Risk 
of malignancy: 5-10% chance of malignancy in each thyroid nodule 
in total population. This risk is higher for males and at extremes of 
age. There is a 33-37 % chance of malignancy in patients with 
history of childhood neck irradiation. A solitary nodule has higher 
incidence of malignancy (15-25%) than multinodular goitre (1-6%). 
A history of rapid increase in size, dyspnea, dysphagia, hoarseness is 
highly suspicious of malignancy. 
CLASSIFICATION  OF  THYROID MALIGNANCIES 
PRIMARY 
1) Arising from the Follicular epithelium 
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a. Well differentiated (90%)-Papillary, Follicular  
b. Undifferentiated (1-2%) - Anaplastic 
2) Arising from Parafollicular cells (5-9%) - Medullary Ca 
3) Lymphoid cells (1-3 %) – Lymphoma 
4) Stromal cells (1%)  
SARCOMAS 
B.Secondary – Metastatic 
ETIOLOGY & RISK FACTORS 
RADIATION EXPOSURE DURING CHILDHOOD 
There is an inverse relationship between risk of thyroid 
carcinoma and age of exposure. The risk is linearly related to 
exposure dose (minimum dose of 10 cGy). Latent period after 
childhood exposure is 3-5 yrs. Majority of cases develop between 
the second and third decade. 
SEX 
Both papillary and follicular carcinomas are approximately 
2.5 times more common in females. The median age at diagnosis is 
earlier in women than in men for both papillary and follicular 
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subtypes and tends to be earlier for papillary cancer as compared to 
follicular cancer in either gender. 
FAMILY HISTORY 
Epidemiological studies have demonstrated a four to 
tenfold increased risk of well- differentiated thyroid cancer in 
first-degree relatives. 
DIET 
Iodine-deficient diets or diets that include a large intake of 
vegetables from the crucifer family may lead to increased TSH 
levels and are considered goitrogenic. Increased iodine intake in 
seafood like shellfish is associated with a higher incidence of 
papillary carcinoma. 
THYROID  ONCOGENESIS[14] 
There are several oncogenes and tumor-suppressor genes 
which are involved in thyroid oncogenesis. 
The RET proto-oncogene located on chromosome 10, 
encodes a receptor tyrosine kinase, which binds several growth 
factors. Germ line mutations in the RET proto- oncogene are 
known to predispose to multiple endocrine neoplasia type 2A 
(MEN 2A), MEN 2B, and familial medullary thyroid cancers. The 
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tyrosine kinase domain of RET can fuse with other genes by 
rearrangement. These fusion products also function as oncogenes 
and have been implicated in the pathogenesis of papillary 
thyroid cancers. BRAF (B- 
type Raf kinase) mutations have recently been identified in 
about 40 percent of papillary thyroid cancers. Mutated ras 
oncogenes have been identified in up to 40 percent of thyroid 
follicular adenomas and carcinomas, papillary and anaplastic 
carcinomas. Mutations of p53 tumor suppressor gene are 
common in undifferentiated thyroid cancers and thyroid cancer 
cell lines. An oncogene resulting from the fusion of the DNA 
binding domain of the thyroid transcription factor PAX8 gene to 
the peroxisome proliferator-activated receptor gamma 1 (PPARγ 
1) has been noted to play an important role in the development of 
follicular neoplasms. 
WELL DIFFERENTIATED THYROID CARCINOMA  (WDC) 
PAPILLARY CARCINOMA THYROID (PTC) 
This carcinoma accounts for 80% to 85% of malignant 
thyroid tumors. It can present as: 
1) Solitary Painless nodule thyroid 
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2) Solitary nodule with lymph node metastasis 
3) Lymph node Metastasis with occult primary 
 PATHOLOGY 
Papillary carcinomas have a variable appearance from 
minute sub capsular white scars to large tumors greater than 5 to 6 
cm that grossly invade surrounding structures. Areas of cystic 
change, calcification, and even ossification may be identified. 
Microscopically, papillary carcinomas are characterized by 
the presence of papillae, but some variants contain no papillary 
areas, are totally follicular inpattern, and are identified as a 
follicular variant. The tumor cells have prominent ovoid nuclei 
with small nucleoli, (Orphan Anne eye nuclei) intranuclear 
grooves, and intranuclear cytoplasmic inclusions. Other  
characteristic features are psammoma bodies and 
multicentricity. Papillary carcinoma has a propensity to invade 
lymphatic spaces and, therefore, leads to microscopic 
multimodal lesions in the gland as well as a high incidence of 
regional lymph node metastases. Papillary carcinomas less than 1 
cm are often referred to as micro carcinoma. 
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ROUTES OF SPREAD 
1) Regional lymph nodes: >80% 
2) Distant metastasis via blood- Rare 
3) Local invasion- Trachea, Esophagus & RLN involvement. 
PATIENT PRESENTING WITH MULTINODULAR GOITRE 
 
FOLLICULAR CARCINOMA 
True follicular thyroid carcinoma is an unusual tumor 
comprising approximately 5% to 10% of thyroid malignancies in 
non endemic goiter areas of the world. Follicular thyroid 
carcinoma is unifocal and thickly encapsulated and shows 
invasion of the capsule and/or blood vessels. At presentation, 
approximately two thirds of patients have disease localized to the 
thyroid. Patients may present with the following: 
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1) Solitary nodule 
2) MNG-Rapid increase in size of a nodule. 
3) Distant metastasis. 
PATHOLOGY 
Microscopically follicular carcinoma thyroid shows 
capsulated follicles with/without colloid. Based on capsular &/ or 
vascular invasion follicular carcinoma is divided into two types. 
Minimally invasive with minimal invasion of blood vessels and 
no breach in the capsule and the more aggressive highly invasive 
variety. In contrast to papillary carcinoma follicular carcinoma is 
unifocal in origin. 
ROUTES OF SPREAD 
1) Haematogenous [90%] - Bone, Lung, Liver 
2) Lymph nodes [10%] – regional 
HURTLE CELL CARCINOMA 
It is a variant of follicular carcinoma. It is found in association 
with Hashimoto‘s thyroiditis, Graves' disease and nodular goitre. It is 
clinically and histologically malignant and FNAC cannot differentiate 
benign from malignant. Treatment includes a total thyroidectomy with 
neck dissection. It is radio resistant. 
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MANAGEMENT OF WELL DIFFERENTIATED 
CARCINOMA 
The mainstay in management of WDC is surgery. However, 
controversy still remains regarding the extent of thyroid tissue 
that should be removed during the initial operation. 
SURGERIES FOR WDC 
1) Total thyroidectomy – involves removal of the entire 
thyroid gland and its capsule. 
2) Near-total thyroidectomy-entire gland is removed 
preserving a small portion near the posterior capsule of the 
thyroid. 
3) Hemithyroidectomy- removal of the lobe ipsilateral to the 
lesion, and removal of the thyroid isthmus. 
Total thyroidectomy may help ensure removal of all 
neoplastic tissue but it leaves the patient with no thyroid tissue, 
necessitating lifelong thyroid hormone supplementation. There is 
also the added to the risk of bilateral dissection of the adjacent 
normal neck structures and damage to important structures. 
Alternatively, more conservative procedures may leave 
inconspicuous residual cancer within the patient. Unfortunately, 
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there are no prospective randomized clinical trials evaluating the 
extent of thyroidectomy, adjuvant radioactive iodide therapy, 
and TSH suppressive therapy. 
According to current recommendation, near-total or total 
thyroidectomy should be carried out in presence of any of the 
following: 
1) Primary thyroid carcinoma more than 1 to 1.5cm in size 
2) Thyroid nodules on the contra lateral lobe 
3) Metastases, either regional or distant 
4) History of radiation therapy to the head and neck 
5) History of differentiated thyroid carcinoma in a first-degree 
relative 
6) Age over 45 years, because of the higher recurrence in and 
above this age 
7) Large tumours (4 cm) with marked atypia on biopsy 
8) Unfavourable histology- tall cell variant, diffuse sclerosing, 
insular variant, poorly differentiated, Hurthle cell 
carcinoma and follicular cancer (except microinvasive) 
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Advantages of Total Thyroidectomy in WDC are 
1) Higher survival rate even for lesions >1.5 cms 
2) Low recurrence rate and prevention of recurrence in contra 
lateral lobe 
3) Decreases incidence of pulmonary metastasis 
4) Can be performed with same morbidity & mortality as 
lobectomy 
5) Improved sensitivity of thyroglobulin (Tg) as marker for 
persistent/recurrent disease 
6) Radioactive iodine can be used to treat persistent/recurrent 
disease. 
Hemithyroidectomy is done in differentiated cancers < 
1.5cm in size without extrathyroidal extension (ETS) and no 
distant metastasis. 
ARGUMENTS FAVORING HEMI-THYROIDECTOMY 
1) Differentiated thyroid cancer is an indolent disease and in a 
majority of patients has a very low recurrence and mortality 
rate. 
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2) Permanent hypoparathyroidism and recurrent laryngeal 
nerve injury are potential complications of total 
thyroidectomy. 
 
 
 32 
LYMPH NODE DISSECTION 
Approximately 80% of patients with PTC have 
microscopic regional lymph node metastases [15]. Microscopic 
occult metastases may often be ablated by adjuvant radioactive  
iodine therapy, but they may also be a site of persistent disease 
that would have easily been removed at the initial operation. 
Gross nodal disease occurs in 20–30% of adult cases of 
PTC, and is certainly justification for lymph node dissection 
[16]. As the central group / level VI of lymph nodes are mainly 
involved in thyroid malignancy it is recommended that dissection 
of ipsilateral central neck nodes and perithyroid lymph nodes 
(Delphian node and lymph nodes medial to the carotid sheath) be 
done in all cases of WDC. Removal of central neck lymph nodes 
is associated with an improvement in the regional recurrence 
rate, and an improved survival rate in retrospective studies [17-
19]. The current American Thyroid Association Guidelines for 
the management of differentiated thyroid cancer now call that a 
staging/prophylactic level VI lymph node dissection for all 
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patients undergoing thyroidectomy for thyroid carcinoma should 
be considered [20]. 
LATERAL NECK NODE DISSECTION 
Dissection of lateral compartment nodes (levels II–V) is 
important for nodes that have identifiable involvement with 
disease. Lymph node level based resections of lateral neck nodes 
are preferable to ―berry-picking‖ if they are clinically involved. 
Prophylactic lateral neck node dissection is not 
recommended as it is not associated with improved overall 
survival. However, follow-up of thyroid cancer patients by 
physical examination and ultrasound can identify patients with 
lateral neck nodal disease that can then be appropriately treated 
by therapeutic compartmental node dissection.  
POSTOPERATIVE MANAGEMENT OF DIFFERENTIATED 
THYROID 
CANCER AND FOLLOWUP 
Thyroid Hormone/ TSH Suppression 
Thyroxine (T4) is given as replacement therapy in patients 
after total or near-total thyroidectomy. In addition it suppresses 
TSH and reducing the growth stimulus for any possible residual 
thyroid cancer cells. TSH suppression reduces tumor recurrence 
 34 
rates, particularly in young patients with papillary and follicular 
thyroid cancer. The goal of should be to keep TSH levels at 
about 0.1 mU/L in low-risk patients, or less than 0.1 mU/L in 
high-risk patients. 
THYROGLOBULIN  MEASUREMENT 
Thyroglobulin is a highly specific marker for follow up. 
Thyroglobulin levels should be below 2 ng/mL when the patient 
is taking T4 and below 5 ng/mL when the patient is hypothyroid. 
A thyroglobulin level above 2 ng/mL is highly suggestive of 
metastatic disease or persistent normal thyroid tissue, especially 
if it increases when TSH levels increase when the patient is 
hypothyroid during preparation for RAI scanning. Thyroglobulin 
and anti-Tg antibody levels should be measured initially at 6-
month intervals and then annually if the patient is clinically 
disease free. 
Rising titers of thyroglobulin or anti- Tg antibodies is highly 
suspicious of recurrence of the disease. 
IMAGING MODALITIES 
High-risk patients should also have an ultrasound of the 
neck and CT or MRI scan of the neck and mediastinum for early 
detection of any persistent or recurrent disease. 
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RADIOACTIVE IODINE SCAN 
Post surgery screening with radioactive iodine 131I is 
more sensitive than chest x-ray or CT scanning for detecting 
metastases. 
Generally, T4 therapy should be discontinued for 
approximately 4-6 weeks prior to scanning with 131I. Patients 
should receive T3 during this time period to decrease the period 
of hypothyroidism. T3 has a shorter half-life than T4 (1 day vs. 
1 week) and needs to be discontinued for 2 weeks to allow TSH 
levels to rise prior to treatment. A low-iodine diet is also 
recommended during this 2-week period. The usual protocol 
involves administering a screening dose of about 2 mCi of 131I 
and measuring uptake 24 hours later. After a total thyroidectomy, 
this value should be less than 1%. A "hot" spot in the neck after 
initial screening usually represents residual normal tissue in the 
thyroid bed. If there is significant uptake, then a therapeutic radio 
ablative dose of 131I should be administered to patients. 
RADIOACTIVE IODINE ABLATION (RIA) 
Radioiodine therapy in form of 131I is the most effective 
non-surgical treatment for differentiated thyroid carcinoma. 131I 
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causes cytotoxicity by the emission of short path length (1–2 mm) 
beta radiation. 131I uptake is dependent upon adequate 
stimulation by TSH, and is reduced in the presence of stable 
iodide. 
RADIO ACTIVE IODINE UPTAKE SCAN OF POST 
THYROIDECTOMY CASE WITH LYMPH NODE METASTASIS 
 
Radioiodine ablation is used increasingly post operatively 
in treatment of well- differentiated thyroid cancer. The goals of 
the treatment are to destroy any residual thyroid tissue and to 
prevent loco regional recurrence. 
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Studies [20] show a benefit with 131I ablation in patients 
with a) larger tumors (greater than 1.5 cm), b) multifocality, c) 
residual disease, and d) nodal metastasis. 
AMERICAN THYROID ASSOCIATION GUIDELINES 
RECOMMENDATIONS FOR RIA 
1) Patients with stage III or IV disease 
2) Patients with stage II disease younger than 45 years 
3) Most of those older than 45 years 
4) Selected patients with stage I disease - tumours >1.5 cm, 
multifocality, residual disease, nodal metastasis, vascular 
invasion, and intermediately differentiated histology [20]. 
Postoperative ablation is typically performed approximately 
6 weeks after near-total or total thyroidectomy. 
Residual/Recurrent thyroid bed disease - 150mCi Diffuse 
Lung Metastasis - <150 mCi. 
Patients with previously positive scans and patients with 
serum thyroglobulin levels greater than 2 ng/mL. usually need 
another 131I treatment after 6 to 12 months until one or two 
negative scans are obtained. 
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SIDE EFFECTS OF RADIOIODINE 
Short term complications include radiation thyroiditis, 
painless neck edema, sialoadenitis, nausea, tumor hemorrhage, 
temporary bone marrow depression and 
amenorrhea/oligomenorrhea. Late complications include 
secondary malignancies bone, soft tissue, colorectal, salivary and 
leukemia. [21] 
THE ROLE OF RADIOTHERAPY AND CHEMOTHERAPY 
FOR WDC 
Radiotherapy in the form of External beam radiotherapy is 
occasionally required to control unresectable, locally invasive or 
recurrent disease and to treat skeletal metastases.  
Single and multidrug chemotherapy has been used with 
little success in disseminated thyroid cancer. Adriamycin and 
Taxol are the most frequently usedagents. 
MANAGEMENT OF PATIENTS WITH METASTATIC 
DISEASE 
The preferred treatment for metastatic disease includes the 
following: 
1) Surgical excision of locoregional disease. Complete 
ipsilateral compartmental dissection of involved 
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compartments with persistent/recurrent disease while 
sparing vital structures is used. Surgery in conjunction 
with additional therapy such as external beam radiation or 
131I is generally advised for tumors invading the upper 
aero-digestive tract. 
2) External beam radiation 
3) Observation of patients with stable asymptomatic disease 
4) Experimental  chemotherapy trials. 
5) A small fraction of patients may benefit from 
radiofrequency ablation, ethanol ablation, or 
chemoembolization. 
TREATMENT OF PULMONARY METASTASES 
The management of patients with pulmonary metastases 
depends upon metastatic lesion size, avidity of radio-iodine 
uptake and response to prior radioiodine therapy. 
Radioiodine therapy should be used to treat pulmonary 
micrometastases, which should be repeated every 6–12 months 
as long as disease continues to respond. Macronodular 
pulmonary metastases may also be treated with radioiodine if 
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demonstrated to be iodine avid. Non radioiodine avid pulmonary 
disease requires chemotherapy. Traditional cytotoxic 
chemotherapeutic agents such as doxorubicin and cisplatin are 
used. 
MANAGEMENT OF THE PATIENT WITH BONE 
METASTASES 
The management of patients with bone metastases depends 
on risk for pathologic fracture, particularly in a weight-bearing 
structure, risk for neurologic compromise from vertebral lesions, 
presence of pain, avidity of radioiodine uptake and potential 
significant marrow exposure from radiation arising from 
radioiodine-avid pelvic metastases. Complete surgical resection 
of isolated symptomatic metastases has been associated with 
improved survival and should be considered, especially in 
patients less than 45 years old. Radioiodine therapy of iodine-
avid bone metastases has been associated with improved survival 
and should be used. External radiation and the concomitant use 
of glucocorticoids should be considered when skeletal metastatic 
lesions arise in locations where acute swelling may produce 
severe pain, fracture, or neurologic complications. Unresectable 
painful lesions can be treated by a combination of options or 
individual therapy that includes radioiodine, external beam 
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radiotherapy, intra-arterial embolization, radiofrequency ablation, 
periodic pamidronate or zoledronate infusions or bone-seeking 
radiopharmaceuticals such as strontium-8 or samarium-153. 
CERVICAL VERTEBRA METASTASIS 
 
TREATMENT OF BRAIN METASTASES 
Brain metastases typically occur in older patients with 
more advanced disease at presentation, and are associated with a 
poor prognosis. Surgical resection and external beam 
radiotherapy traditionally have been the mainstays of therapy. 
Targeted approaches (such as radiosurgery) are employed to limit 
the radiation exposure of the surrounding brain tissue. 
Radioiodine can be considered for CNS metastases that concentrate 
radioiodine. 
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AMERICAN JOINT COMMITTEE ON CANCER (AJCC) 
CLASSIFICATION OF THYROID CANCER[22] 
PRIMARY TUMOR (T) 
TX Primary tumor cannot be assessed T0 No evidence of 
primary tumor 
T1 Tumor < 2 cm confined to the thyroid 
T2 Tumor >2 cm and <4 cm confined to the thyroid T3 Tumor 
>4 cm confined to the thyroid 
T4a Tumor of any size with extra thyroid extension to 
subcutaneous soft tissues, larynx, trachea, esophagus, or 
recurrent laryngeal nerve or Intrathyroidal Anaplastic 
carcinoma 
T4b Tumor invading prevertebral fascia or encases carotid artery 
or mediastinal vessels or Extrathyroidal Anaplastic 
carcinoma 
REGIONAL LYMPH NODES (N ) 
(Central Compartment, Lateral Cervical, And Upper 
Mediastinal) 
NX Regional lymph nodes cannot be assessed N0 No regional 
lymph node metastasis 
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N1 Regional lymph node metastasis 
N1a Metastasis to level VI (pre- or paratracheal, and 
prelaryngeal) 
N1b Metastasis to contra lateral cervical or superior mediastinal 
lymph nodes 
DISTANT  METASTASIS (M) 
MX Distant metastasis cannot be assessed  
M0 No distant metastasis 
M1 Distant metastasis 
STAGE GROUPINGS 
PAPILLARY AND FOLLICULAR 
Under 45 years of age 
Stage I Stage II Any T Any T Any N Any N M0 M1 
45 years of age and over 
Stage I 
 
T1 
 
N0 
 
M0 
Stage II T2 N0 M0 
Stage III 
 
 
 
 
 
T3 
T1 
T2 
T3 
T4a 
T4a 
N0 
N1a 
N1a 
N1a 
N0 
N1a 
M0 
M0 
M0 
M0 
M0 
M0 
 44 
Stage I Stage II Any T Any T Any N Any N M0 M1 
Stage IVA 
 
 
 
 
Stage IVB 
T 
T2 
T3 
T4a 
T4a 
T4b 
N1b 
N1b 
N1b 
N1b 
N1b 
Any N 
M0 
M0 
M0 
M0 
M0 
M0 
Stage IVC Any T Any N M1 
MEDULLARY  CARCINOMA 
Stage I T1 N0 M0 
Stage II 
 
Stage III 
 
 
Stage IVA 
 
 
 
 
 
Stage IVB 
T2 
T3 
T1 
T2 
T3 
T4a 
T4a 
T1 
T2 
T3 
T4a 
T4b 
N0 
N0 
N1a 
N1a 
N1a 
N0 
N1a 
N1b 
N1b 
N1b 
N1b 
Any N 
M0 
M0 
M0 
M0 
M0 
M0 
M0 
M0 
M0 
M0 
M0 
M0 
Stage IVC Any T Any N M1 
ANAPLASTIC  CARCINOMA  
Stage IVA T4a Any N M0 
Stage IVB T4b Any N M0 
Stage IVC Any T Any N M1 
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PROGNOSIS OF WDC 
In the overall population with papillary thyroid cancer, there 
is a 90% to 95% long- term disease-free survival; there is a 70% to 
80% long-term disease-free survival for patients with follicular 
cancers. 20% of patients in this group who develop recurrent 
disease include a majority with local cervical recurrences either in 
lymph nodes or the thyroid bed and a minority of patients with 
distant metastases to the lung, bone, and liver. 
PROGNOSTIC FACTORS 
AMES  criteria  (Lahey  Clinic) based on age, metastatic   
disease, Extrathyroidal extension and size. 
 Low Mortality Risk High Mortality Risk 
A: Age Men <41years 
Women <51 years 
Men > 41 years 
Women >51years 
M: 
Metastasis 
Absence of distant 
metastasis 
Presence of distant 
metastasis 
E: Extent of 
primary 
tumor 
Intrathyroidal papillary 
cancer Follicular cancer 
with minor capsular 
Involvement 
Extrathyroidal papillary 
cancer Follicular cancer 
with major capsular 
involvement 
S: Size of 
primary 
tumor 
< 5cm ≥ 5 cm (regardless of 
extent) 
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Low-risk patients can be identified as those who have a 
long-term overall survival rate of 98% and overall disease-free 
survival of 95% as compared to 54% and 45%, respectively,  for 
high-risk patients. 
AGES Criteria (Mayo Clinic) - A mathematical formula based 
on weighted risk factors was developed to yield a prognostic 
score. Based on age, tumor grade,tumor extent and tumor size 
Score= 0.05 x Age [if age >40]+ 1[if Grade 2] +3 [if Grade 3 
or 4]+1 [if extra thyroid] 
+ 3 [if distant metastasis]+ 0.2x tumour size[ maximum 
diameter in cm] 20yr survival score: 
<3.99- 99% 
4-4.99- 80% 
5-5.99 – 67% 
> 6 – 13% 
The MACIS scale is a more sophisticated postoperative 
system modified from the AGES scale. This scale incorporates 
distant metastases, age at presentation, completeness of original 
surgical resection, extrathyroidal invasion, and size of original 
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lesion (in centimeters) and classifies patients into four risk-
groups based on their scores 
OTHER PROGNOSTIC SCORING SYSTEMS 
Ohio State Size, cervical metastases, multiplicity, invasion, 
distant metastases Sloan-Kettering Age, histology, size, 
extension, metastases NTCTS Size, multifocality, invasion, 
differentiation,  cervical metastases, extracervical metastases 
METASTASIS 
Approximately 33% to 61% of patients with PTC will have 
involvement of cervical lymph nodes at the time of diagnosis. Whereas 
in follicular cancers is lower, ranging between 5% and 20%. Only a 
small minority of patients have distant metastatic hematogenous disease 
at the time of diagnosis. Having distant metastases at the time of 
presentation is a strong predictor of very poor outcome. 
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POORLY DIFFERENTIATED THYROID CARCINOMA 
ANAPLASTIC CARCINOMA 
It is a lethal malignancy with the worst prognosis of all 
thyroid malignancies. The median survival is 4 to 5 months from 
diagnosis. The mean age of diagnosis is the sixth and seventh 
decade with male to female ratio of 1: 1.5. It usually develops 
via dedifferentiation of prior well differentiated carcinoma. 25-
50% have pulmonary metastases at the time diagnosis. Other 
organs of metastasis include bone and liver. 
Microscopy shows anaplastic cells with marked cytologic 
atypia and high mitotic activity. Tumour necrosis and vascular 
invasion are common. A third of cases show coexisting areas of 
well differentiated thyroid carcinoma 
CLINICAL FEATURES 
The patients present with a palpable mass that is rapidly 
increasing in size. Invasion into the trachea, larynx, or recurrent 
laryngeal nerve leads to obstructive symptoms, hemoptysis,  
dysphagia, and hoarseness, which are often present at diagnosis. 
The majority of patients with ATC die from aggressive 
local-regional disease, primarily with upper airway respiratory 
failure. 
 49 
TREATMENT 
Aggressive local therapy is indicated in all patients who can 
tolerate it and in whom it is technically possible. Survival after 
the diagnosis of ATC is very poor. External radiation has been 
used with limited success to treat locally recurrent ATC. 
Doxorubicin is the single most effective chemotherapeutic for 
ATC, and it has been shown that doxorubicin plus platinum is 
more effective than doxorubicin alone. 
MEDULLARY THYROID CARCINOMA (MTC). 
This variety arises from the parafollicular (‗c cells‘). It has 
an incidence of 3-12% of thyroid cancers. There are two types of 
MTC namely sporadic/non familial (60-70%) and Familial(30%) 
There are 3 distinct syndromes associated with familial 
MTC- MEN 2A, MEN 2B and Familial non MEN MTC. All these 
variants are known to result secondary to germline mutations in 
the RET proto-oncogene. 
PATHOLOGY 
MTCs typically are unilateral (80%) in patients with 
sporadic disease and multicentric in familial cases, with bilateral 
tumors occurring in up to 90% of familial patients. Familial 
cases also are associated with C-cell hyperplasia, which is 
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considered a premalignant lesion. Microscopically, tumors are 
composed of sheets of infiltrating neoplastic cells separated by 
collagen and amyloid. The presence of amyloid is a diagnostic  
finding, but immunohistochemistry for calcitonin is more 
commonly used as a diagnostic tumor marker. These tumors also 
stain positively for CEA and calcitonin  gene–related peptide. 
CLINICAL FEATURES 
Most patients present between 50 and 60 years old, 
although patients with familial disease present at a younger age. 
Patients with MTC often present with a neck mass that may be 
associated with palpable cervical lymphadenopathy (15 to 20%). 
Pain or aching is more common in patients with these tumors, and 
local invasion may produce symptoms of dysphagia, dyspnea, or 
dysphonia. Distant blood-borne metastases to theliver, bone 
(frequently osteoblastic), and lung occur later in the disease. 
Patients with extensive metastatic disease frequently develop 
diarrhea, which may result from increased intestinal motility and 
impaired intestinal water and electrolyte flux. About 2 to 4% of 
patients develop Cushing's syndrome as a result of ectopic 
production of adrenocorticotropic  hormone (ACTH). 
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TREATMENT 
If patients are found to have a pheochromocytoma, this 
must be operated on first. Total thyroidectomy is the treatment 
of choice for patients with MTC. Central compartment nodes 
frequently are involved early in the disease process, so that a 
bilateral central neck node dissection should be routinely 
performed. In patients with palpable cervical nodes or involved 
central neck nodes, ipsilateral or bilateral, modified radical neck 
dissection is recommended. In patients with tumors >1 cm, 
ipsilateral prophylactic modified radical neck dissection is 
recommended because >60% of these patients have nodal 
metastases. In the case of locally recurrent or metastatic disease, 
tumor debulking is advised not only to ameliorate symptoms of 
flushing and diarrhea, but also to decrease risk of death from 
recurrent central neck or mediastinal disease. 
Radiotherapy -External beam radiotherapy is controversial, 
but is recommended for patients with unresectable residual or 
recurrent tumor. 
There is no effective chemotherapy regimen. 
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In patients who have hypercalcemia at the time of 
thyroidectomy, only obviously enlarged parathyroid glands 
should be removed. 
Patients are followed by annual measurements of 
calcitonin and CEA levels, in addition to history and physical 
examination. 
THYROID LYMPHOMA 
Thyroid Lymphoma is rare constituting < 1% of all 
lymphomas. Majority are non- Hodgkin's lymphoma of 
intermediate grade. Many are considered mucosa-associated 
lymphoid tissue lymphomas (MALTomas) that show plasmacytic 
differentiation and may be associated with similar lesions in 
extranodal sites especially in the gastrointestinal tract. The 
majority have thyroid disease plus cervical or mediastinal lymph 
nodes. Thyroid lymphomas have a strong female predominance, 
ranging from 3:1 up to 8:1 in the 6th and 7th decade of life. 
Symptoms include hoarseness, dyspnea with stridor, or dysphagia. 
Patients may be hypothyroid with Hashimoto's thyroiditis. 
Treatment includes combination of surgery, EBRT combined 
with a chemotherapy regimen based on the histopathological 
subtype of lymphoma. 
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METASTATIC CARCINOMA TO THYROID [23,  24] 
Comprises less than 1% of thyroid malignancies. The most 
common primary site is renal cell carcinoma, accounting for 
23% of cases. The next most common sites are breast (16%), 
lung (15%), melanoma (5%), and colon and larynx (4.5% each). 
Diagnosis is by FNAC. Treatment is mainly palliative.  Surgery 
maybe indicated in case of obstructive symptoms. 
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MATERIALS AND METHODS 
This prospective study included 100 patients presenting 
with thyroid swellings clinically suspicious of malignancy at the 
Institute of general surgery,Madras medical college. Duration of 
study was June 2014 to Dec 2015 which included a 6 month 
follow up. 
INCLUSION CRITERIA 
The patients admitted with thyroid swelling  in various 
surgical wards in RGGGH.  
All cases must be clinically and biochemically euthyroid 
EXCLUSION CRITERIA 
Those cases not in euthyroid state. 
All patients were admitted and a detailed history and 
clinical examination was done and investigated as per the written 
proforma. Informed consent was taken and thyroid profile and 
ultrasonogram ,FNAC was done in all cases. All cases that gave 
consent for surgery were explained about risk and complications 
of surgery and anesthesia. Preoperatively investigations were sent 
according to protocol. A preoperative indirect laryngoscopy was 
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done in all cases to check for the status of vocal cords. The type 
of surgery depended on the clinical diagnosis and FNAC report. 
Correlation of the clinical diagnosis, preoperative TSH 
levels,radiological,cytology and the final histopathological 
diagnosis was done. Patients were followed up regularly over a 
minimum period of 6 months. Follow up was done at regular 
interval by clinical examination, serum thyroglobulin estimation, 
serum TSH levels and thyroid scan. 
STATISTICAL METHODS 
Descriptive and inferential statistical analysis has been 
carried out in the present study. Results on continuous 
measurements are presented on Mean  SD (Min-Max) and 
results on categorical measurements are presented in Number (%). 
Significance is assessed at 5 % level of significance. 
Student t test (two tailed, independent) has been used to find 
the significance of study parameters on continuous scale between 
two groups Inter group analysis) on metric parameters. Leven1s 
test for homogeneity of variance has been performed to assess 
the homogeneity of variance. Chi-square/ Fisher Exact test has 
been used to find the significance of study parameters on 
categorical scale between two or more groups. 
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SIGNIFICANT FIGURES 
+ Suggestive significance (P value: 0.05<P<0.10) 
* Moderately significant (P value: 0.01<P  0.05) 
** Strongly significant (P value: P0.01) 
Statistical software: The Statistical software namely SAS 
9.2, SPSS 15.0, Stata 10.1, MedCalc 9.0.1 ,Systat 12.0 and R 
environment ver.2.11.1 were used for the analysis of the data 
and Microsoft word and Microsoft Excel have been used to 
generate graphs, tables etc. 
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OBSERVATION AND RESULTS 
This was a prospective study done in the Department of 
General Surgery at Madras medical college,Chennai. The study 
period was June 2014 to June 2015. 
Total number of cases - 100 
Total number of confirmed malignancy – 25 
Cases who were histopathologically proven to be malignant 
were retrospectively studied.Their clinical features,radiological 
findings and pr operative serum TSH levels were analysed. 
STUDY DESIGN 
A prospective study with a sample size of 100 patients was 
conducted at the Institute of General surgery,Madras Medical 
College,Chennai . Patients with clinical features suggestive of thyroid 
malignancy were included. The preoperative clinical,radiological and 
TSH levels were analyzed to check for any relationship between them 
and the likelihood of a thyroid nodule being malignant. At the same 
time a clinical study of those patients with confirmed thyroid 
malignancy was done. The observed results were subjected to 
statistical analysis. The following observations were made. 
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RESULTS 
 AGE DISTRIBUTION AMONG MALIGNANCY PATIENTS 
Age in years  
Malignant 
(n=25) 
Percentage (%) 
<60 9 36% 
>60 16 64% 
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SEX DISTRIBUTION  AMONG  MALIGNANCY  PATIENTS 
Sex Malignant (n=25) Percentage 
Male 4 16% 
Female 21 84% 
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TYPE OF GOITRE AND MALIGNANCY 
Type of Goitre No of Malignancy Patients Percentage 
MNG 10 40% 
SNT 15 60% 
DIFFUSE 0 0% 
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FIXITY AMONG MALIGNANCY PATIENTS 
Fixity Malignant (n=25) Percentage 
MOBILE 12 48% 
FIXED 13 52% 
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LYMPHADENOPATHY IN MALIGNANCY 
Lymphadenopathy Malignant(n=25) Percentage 
ABSENT 9 36% 
PRESENT 16 64% 
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SONOGRAPHIC FINDINGS MARGINS IN USG   AMONG 
MALIGNANCY PATIENTS 
Margin Malignant(n=25) Percentage 
IRREGULAR 19 76% 
WELL DEFINED  6 24% 
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ECHOGENICITY IN SONOGRAPHY AMONG 
MALIGNANCY PATIENTS 
 
Echogenicity Malignant(n=25) Percentage 
HYPOECHOEIC 16 64% 
HYPERECHOEIC 9 36% 
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CALCIFICATION IN USG AMONG MALIGNANCY 
PATIENTS 
 
 
Calcification Malignant (n=25) Percentage 
PRESENT 17 68% 
ABSENT 8 32% 
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INVASION TO ADJACENT STRUCTURES SEEN IN USG 
AMONG MALIGNANCY PATIENTS 
 
 
Invasion to adjacent 
structures 
Malignant(n=25) Percentage 
PRESENT 19 76% 
ABSENT 6 24% 
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SERUM TSH LEVELS AMONG MALIGNANCY PATIENTS 
TSH levels Malignant(n=25) Percentage 
0.4-0.9 3 12% 
1.0-1.7 8 32% 
1.8-5.5 14 56% 
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DISCUSSION 
PREDICTORS OF MALIGNACY IN THYROID NODULES 
There are many predictors of malignancy in a thyroid 
nodule. A history of prior radiation exposure especially during 
childhood is known to be found in many cases of papillary 
carcinoma. Similarly, exposure to certain environmental risk 
factors such as excess dietary intake of iodine, retinol and vitamin 
E has shown to have an increased chance of malignancy.  
Age factors: Younger age group (<20 years) and older age 
group (>70years) have a higher risk of malignancy. 
Associations with other inherited syndromes such as 
familial polyposis coli, Gardner‘s syndrome and Cowden‘s 
syndrome is seen with medullary carcinoma thyroid.  
In the presence of certain clinical signs and symptoms i.e. 
hard and fixed nodules, large nodules (>4cm) with presence of 
neck lymph nodes,solitary thyroid nodule, rapid increase in size 
of thyroid nodules, associated hoarseness of voice, dysphagia, 
dyspnea and Horner‘s syndrome malignancy should always be 
suspected. 
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Suspicious criteria by ultrasound include central 
hypervascularity, microcalcifications smaller than 2mm in 
diameter, irregular borders,hypoechoic lesions and invasion into 
surrounding tissues. [28, 29] Ultrasound scan is more sensitive than 
clinical examination in the detection of enlarged cervical nodes. 
Cervical lymph nodes, infiltrated by papillary carcinoma may be 
entirely cystic and mimic other cystic masses of the neck, such as 
a branchial cyst, while calcification may be seen within nodes 
invaded by medullary carcinoma. 
SERUM TSH LEVELS – A NOVEL METHOD IN 
PREDICTING MALIGNANCY 
Many studies have shown a definite relation between 
preoperative serum TSH levels and thyroid malignancy. 
Furthermore, preoperative serum TSH concentrations are higher 
in patients with more aggressive tumors. Thus a baseline TSH 
would predict which nodules require a more aggressive approach 
and surgery. 
RATIONAL BEHIND CHOOSING TSH LEVELS AS A 
PREDICTOR OF MALIGNANCY 
TSH is a known thyroid growth factor. Well-differentiated  
thyroid  cancers  express TSH receptors [30, 31]. Although oncogenes 
and other growth factors are involved in thyroid cancer growth and 
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development [32, 33], it seems probable that TSH can act as a cancer 
stimulus. This hypothesis is supported by improved survival in 
thyroid cancer patients treated with suppressive doses of 
levothyroxine [34] and by cases of tumor growth post-T4 withdrawal 
or recombinant TSH [35]. Some studies have showed higher serum 
TSH levels associated with advanced stages of thyroid cancer. 
These findings suggest that TSH may play a central role in the 
development and /or progression of thyroid carcinomas. 
Supportive of the TSH receptor‘s role in cancer are the 
data on autoimmune thyroid disease and thyroid cancer. An 
increased incidence of thyroid cancer is seen in patients  with 
antibody evidence of Hashimoto‘s thyroiditis. 
Our Study: In this study we had a total of 100 patients 
who presented with thyroid swelling. The main objective was to 
evaluate the role of TSH as a biochemical predictor of 
malignancy and also study about the clinical radiological 
features that can predict thyroid malignancy. Only patients that 
were euthyroid were included. 
Of those patients with confirmed malignancy a descriptive 
analysis of the clinical presentation and management was done. 
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The observations and results were subjected to  statistical analysis 
and compared with other studies. 
GENDER  DISTRIBUTION: 
There were 21 female patients and 4 male patients in this 
study histopathologically proven malignancy. This distribution is 
comparable to other studies 
COMPARISON OF GENDER DISTRIBUTION OF 
MALIGNANT CASES 
Study Year Male: Female Ratio 
Jemal et al 2003 1:3 
Dorairajan et al 2002 1:3.5 
Our study 2015 1:5.5 
It is well established that thyroid disorders including thyroid 
malignancies are more common among women than men.But still 
the cause of this increased prevalence of thyroid cancers among 
women is unclear .In our study,incidence of malignancy is more 
common among females as compared with previous 
studies.Application of genomic and proteomic approaches to the 
study of thyroid cancer gender disparity could be helpful for better 
understanding the molecular basis for gender differences in thyroid 
cancers (Rahbari R,Zhang L,Kebebew E) 
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AGE DISTRIBUTION 
The mean age for thyroid malignancy was 50 years which was 
comparable to other studies [3, 37, 38].Mean age in males was 59 years 
whereas in females was  55. 
Study Year Mean age 
Haymart et al(3) 2008 46 
Fiore et al (42) 2009 45 
Our study 2015 50 
Thyroid cancer incidence in males is strongly related to age 
with highest incidence rates being in older men.However incidence 
in females does not entirely follow the pattern of increasing 
incidence in age seen in males(and in most other 
cancers).Hormonal factors may be implicated in the association 
with age in females. 
In our study,most of the malignant patients fall in age group 
>60 years.The mean age of malignancy was found to  be lower in 
females than in males as shown in previous studies. 
TYPE OF GOITRE AND ITS INCIDENCE OF MALIGNANCY 
Clinically recogonised thyroid cancer constitutes less than 1% 
of human malignancies.Risk of malignancy in solitary nodule 
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thyroid is greater than other swellings. Risk of malignancy in 
generalized swelling is about 3% and in solitary nodule thyroid is 
about 15%.In a study done by :Lema,L.E.K.; M.R. Aziz; N.A. 
Mbembati; H.A. Mwakyoma: malignancy was found in 10% of   
solitary nodule thyroid and 5% of multinodular goiter.  
Well differentiated cancers are common among thyroid 
cancers.Among the well differentiated cancers papillary carcinoma 
is more common which usually presents as solitary nodule.Hence 
In our study among the malignancy patients 60%  are SNT 
and remaining had multinodular goiter. 
 
 
 74 
CERVICAL LYMPH NODE INVLOVEMENT 
Cervical lymphadenopathy is a common presentation in 
thyroid malignancy. 
Approximately 33% to 61% of patients with papillary 
carcinoma will have involvement of clinically apparent cervical 
lymph nodes at the time of diagnosis as per previous studies.  
COMPARISION OF INCIDENCE OF CERVICAL LYMPH 
NODE  INVOLVEMENT 
Study Year Percentage 
Mazzaferri et al (41 2001 53-61% 
Dorairajan et al(37) 2002 26-50% 
Our study 2015 64% 
      Appeareance of enlarged cervical lymph nodes on 
ultrasound boosted the predictive value of diagnosing thyroid 
cancer in suspicious nodules. 
 The incidence of neck nodes in our study was 64% 
 Presence of neck lymph nodes was a significant clinical 
indicator of malignancy Hence assessment of enlarged 
cervical lymph nodes by ultrasound is feasible and should be 
studied further to determine the exact clinical and 
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pathological implications of cervical  lymph nodes found on 
pre operative ultrasound 
RADIOLOGICAL FEATURES PREDICTING THYROID 
MALIGNANCY 
According to Leenhardt et al ,the incidence of malignancy is 
4% when a solid thyroid nodule is hyperechoic. If the lesion is 
hypoechoic, the incidence of malignancy rises to 26% . However, 
hypoechogenicity alone is inaccurate in predicting malignancy, and 
if used as a sole predictive sign, it has a relat ively poor specificity 
(49%) and positive predictive value (40%) .  
In our study,64% of the malignancy patients have hypoechoic 
lesion. 
A malignant thyroid nodule tends to have ill-defined margins 
on ultrasound. A peripheral halo of decreased echogenicity is seen 
around hypoechoic and isoechoic nodules and is caused by either 
the capsule of the nodule or compressed thyroid tissue and vessels. 
The absence of a halo has a specificity of 77% and sensitivity of 
67% in predicting malignancy. 
In our study,19 out of 25 malignancy patients have irregular 
margins in ultrasound. 
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Fine punctate calcification due to calcified psammoma bodies 
within the nodule is seen in papillary carcinoma in 25%–40% of 
cases. If used as the sole predictive sign of malignancy, 
microcalcification is the most reliable one with an accuracy of 76%, 
specificity of 93% and a positive predictive value of 70%. Coarse, 
dysmorphic or curvilinear calcifications commonly indicate 
benignity. 
 
In our study,68% of the malignancy patients have micro 
calcification on sonography. 
Invasion to adjacent structures such as trachea,oesophagus 
and  major vessels such as carotid is a important featrure of 
malignancy and is considered as a key predictor of thyroid 
malignancy. 
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In this study 19 out of 25 patients have invasion to adjacent 
structures. 
TSH LEVELS AND THE RISK OF MALIGNANCY 
In this study the mean preoperative TSH  value  was:  
2.39±1.42mU/L.  All  patients were euthyroid. The mean TSH value 
was significantly higher in malignancy than in benign disease i .e. 
3.71±1.22mU/L vs. 1.80±1.03mU/L. This is comparable to  the 
results of Haymart et al (3), Fiore et al (42)  and Jonklaas et al  (34) 
TABLE 24 COMPARISON OF MEAN TSH VALUE IN 
BENIGN VS MALIGNANT DISEASE 
 Benign disease 
Malignant 
disease 
P value 
Our Study 1.80±1.03 3.71±1.22 P<0.001 
Haymart et al 
(3) 
1.4±0.4 3.7±2.3 P<0.001 
Fiore et al 
(42) 
0.70 ± 0.41 1.10±0.6 P<0.0001 
On analysis of the preoperative TSH values it was 
observed that TSH level was an independent predictor of 
malignancy. Patients with values of 0.40-1.39 mU/L had 0% 
chance of malignancy. Those with range of 1.40-4.99mU/L had 
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36.7% chance of malignancy whereas those with TSH levels 
>5mU/L had 75% chance of malignancy 
The following table shows the various studies that have 
shown a relationship between serum TSH concentration and 
thyroid cancer. 
SUMMARY OF STUDIES INVESTIGATING THE 
RELATIONSHIP BETWEEN SERUM TSH 
CONCENTRATION AND THYROID CANCER [2] 
Authors Journal 
No. of 
patients 
Country 
Significant 
findings 
Boelaert  
et al. 
(2006)(2) 
Journal of 
Clinical 
Endocrinology 
and 
Metabolism 
1500 UK Serum TSH 
is independent 
predictor of 
malignancy in 
thyroid nodules. 
Risk of 
malignancy rises 
in parallel with  
serum  TSH 
within normal 
range. 
Haymart  
et al. 
(2008a)(3) 
Journal of 
Clinical 
Endocrinology 
and 
Metabolism 
843 US Likelihood of 
thyroid cancer 
increases with 
higher TSH 
concentration. 
Higher serum 
TSH  associated 
with advanced 
stage- 
differentiated 
thyroid cancer 
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Authors Journal 
No. of 
patients 
Country 
Significant 
findings 
Jonklaas  
et al. 
(2008)(34) 
Thyroid 50 US Higher TSH 
concentrations 
are associated 
with diagnosis 
of thyroid cancer. 
Patients with 
thyroid cancer 
have lower serum 
total T3 
Concentrations 
Polyzos et 
al. 
(2008)(5) 
Journal of 
Cancer 
Research and 
Clinical 
Oncology 
565 Greece Higher rates of 
thyroid 
malignancy in 
patients with 
TSH in upper 
tertile of normal 
range 
Haymart  
et al. 
(2008b)(3) 
Clinical 
Endocrinology 
1361 US Thyroid cancer 
incidence 
correlates with 
serum TSH 
independent of 
age. Higher  TSH  
is  associated   
with 
Extrathyroidal 
extension of 
disease. 
Fiore et 
al. (2009) 
(42) 
Endocrine- 
Related 
Cancer 
10 178 Italy Higher TSH in 
patients with T3– 
T4 disease   and   
in  those with 
lymph node 
metastases. 
Autonomously 
functioning 
thyroid nodules 
are less likely  to 
be malignant 
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SUMMARY 
This was a prospective study involving 50 patients 
admitted to our hospital with thyroid swellings. The aim was to 
evaluate the utility of serum TSH estimation as a biochemical 
predictor of malignancy in suspicious thyroid nodules and to 
study the clinical presentation of thyroid malignancies.Also 
other predictors such as clinical features and radiological 
features were studied. The observations of this study can be 
summarized as follows: 
 Most patients were females with mean age of 44.62±15.12 
years. Mean age of malignancy was 4o years with a higher 
mean age in males (59 years) as compared to females (38 
years). 
 Commonest presentation was a rapidly growing thyroid 
swelling of short duration. In some cases there was history 
of a longstanding goitre with sudden development of 
secondary symptoms such as pain and compressive 
symptoms. 
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 Majority of malignancy patients presented with a SNT. 
60% of the malignancy patients presented with SNT. 
 Most of the malignancy patients presented with 
lymphadenopathy.64% of  malignancy patients had 
cervical lymphadenopathy. 
 Papillary carcinoma was the most common histopathological 
type. 
 The mean preoperative TSH value was 2.39±1.42 mU/L. 
 Mean TSH value in malignancy was higher 
(3.71±1.22mU/L) compared to those with benign disease 
1.80±1.03mU/L) 
 Incidence of malignancy increased with higher TSH values. 
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CONCLUSION 
Thyroid malignancies have a varied clinical presentation. 
The commonest presentation being that of a solitary thyroid 
nodule. 
Though there are many predictors of thyroid malignancy, 
none of them can conclusively predict the nature of a thyroid 
nodule. 
In our study we evaluated the utility of preoperative serum 
TSH levels as a predictor of malignancy and it did show a 
statistically significant correlation (P=<0.01) between higher 
TSH levels and malignant nodules. However this relationship 
between higher TSH levels was not seen in those presenting with 
no primary thyroid swelling and only cervical lymph node 
metastasis. The utility of TSH in poorly differentiated carcinoma 
could not be assessed as all the patients in this series had well 
differentiated carcinoma. 
However, as all patients with a thyroid swelling undergo a 
thyroid function test it is important to pay special attention to 
the TSH values. . TSH levels could be used as predictor  in 
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clinically suspect malignant thyroid swelling with a benign FNAC 
report. In such cases where TSH value is high, the FNAC can be 
relooked to confirm the diagnosis. 
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ANNEXURE 
DATA COLLECTION SHEET 
I.Patient particulars: 
Name                              DOA                        Case No. 
Age                                DOS                       I.p.No. 
Sex                                    DOD     
Address 
Occupation: 
CHIEF COMPLAINTS 
HISTORY OF PRESENTING ILLNESS 
Duration /Progression 
Pressure symptoms-dyspnoea/dysphagia 
Symptoms of hyperthyroidism/hypothyroidism 
Symptoms suggestive of malignancy 
Other symptoms 
PAST HISTORY 
History  of previous thyroid disorder 
History of goitrogen intake 
Drug history 
Radiation exposure 
MENSTRUAL HISTORY 
FAMILY HISTORY 
PERSONAL HISORY 
Diet 
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Sleep 
Apetite 
Bladder/Bowel habits 
EXAMINATION 
Appearance,build,nutritional assessment 
Pallor/Icterus/Cyanosis/Clubbing/Edema/Lymphadenopathy 
Vitals:Pulse rate/BP/Respiratory rate 
LOCAL EXAMINATION 
Inspection 
a.Site 
b.Size 
c.Shape 
d.Surface 
e.Extent 
f.Margins 
g.Skin over the swelling 
h.Pulsation 
i.Movement with deglutition 
j.Position of trachea 
Palpation 
a.Local temperature 
b.Tenderness 
c.Site, size, shape and extent 
d.Surface 
e.Borders 
f.Consistency 
g.Mobility 
h.Fixity to skin 
i.Plane of the swelling 
j.Examination of lymph nodes 
k.Tracheal position 
l.Carotid pulsation 
Percussion 
Auscultation 
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SYSTEMIC EXAMINATION 
INVESTIGATIONS: 
Blood routine 
Chest x ray/Xray neck AP and lateral view 
Indirect laryngoscopy 
Thyroid profile-TSH,T3,T4 
FNAC 
FINAL DIAGNOSIS 
MANAGEMENT 
Operated /Non operated- 
POST OPERATIVE COURSE 
Recovery 
Complications 
FOLLOW UP 
TSH concentration 
Thyroglobulin 
NAME AGE SEX TYPE OF GOITRE FIXITY LYMPHADENOPATHY MARGINS ECHOES CALCIFICATION INVASION TSH MALIGNANCY
SARASWATHY 64 F MNG MOBILE NEGATIVE REGULAR HYPER NO NO 1.3 NO
KAMATCHI 34 F MNG MOBILE NEGATIVE REGULAR HYPER NO YES 1.9 NO
JAGAN 36 M SNT MOBILE NEGATIVE REGULAR HYPER NO NO 1.8 NO
VALLI 65 F SNT MOBILE NEGATIVE IRREGULAR HYPO YES YES 1.7 YES
VANATHI 45 F DIFFUSE MOBILE NEGATIVE REGULAR HYPER NO NO 1.5 NO
SURESH 51 M MNG MOBILE NEGATIVE REGULAR HYPO NO NO 1.23 NO
MUNIAMMAL 60 F MNG MOBILE NEGATIVE REGULAR HYPER NO NO 0.8 NO
MEENAKSHI 48 F SNT MOBILE NEGATIVE REGULAR HYPER NO NO 1.54 NO
MARY 54 F MNG MOBILE POSITIVE IRREGULAR HYPER NO NO 1.38 NO
JOTHI 22 F MNG MOBILE NEGATIVE REGULAR HYPER YES NO 1.41 NO
AARTHI 40 F MNG FIXED POSITIVE IRREGULAR HYPER NO NO 1.6 YES
ARUN PRASATH 34 M SNT MOBILE NEGATIVE REGULAR HYPO NO YES 0.85 YES
ANITHA 26 F MNG MOBILE NEGATIVE REGULAR HYPER NO NO 1.27 NO
JAYALAKSHMI 61 F SNT MOBILE NEGATIVE REGULAR HYPER NO NO 1.11 NO
BHAIRAVI 36 F MNG MOBILE NEGATIVE REGULAR HYPER NO NO 0.5 NO
MUTHULAKSHMI 62 F SNT MOBILE NEGATIVE IRREGULAR HYPER YES NO 2.9 YES
FATHIMA 27 F DIFFUSE MOBILE NEGATIVE REGULAR HYPER YES NO 1.56 NO
BHANU 34 F MNG MOBILE NEGATIVE REGULAR HYPO NO NO 2.2 NO
VIGNESH 26 M SNT MOBILE NEGATIVE REGULAR HYPER NO NO 0.9 NO
RAJESHWARI 63 F MNG MOBILE NEGATIVE IRREGULAR HYPER NO NO 1.64 NO
SHANTHI 33 F SNT FIXED NEGATIVE REGULAR HYPER YES NO 3.1 YES
VIJAYA 38 F MNG MOBILE NEGATIVE REGULAR HYPER NO NO 1.32 NO
JANAKI 41 F MNG MOBILE NEGATIVE REGULAR HYPER NO NO 1.27 NO
SANTHOSH 21 M SNT MOBILE NEGATIVE REGULAR HYPER NO NO 0.64 NO
ARASI 62 F MNG MOBILE NEGATIVE REGULAR HYPER NO NO 1.48 NO
VENDA 65 F MNG MOBILE NEGATIVE IRREGULAR HYPO NO NO 2.1 NO
RAJALAKSHMI 49 F SNT MOBILE NEGATIVE REGULAR HYPER NO NO 1.57 NO
MUNIYANDI 70 M MNG MOBILE POSITIVE IRREGULAR HYPO NO YES 1.4 YES
LAKSHMIPRIYA 66 F SNT FIXED NEGATIVE IRREGULAR HYPO NO NO 3.8 YES
NOOR JAHAN 54 F MNG MOBILE NEGATIVE REGULAR HYPER NO NO 0.82 NO
ARJUN 19 M MNG MOBILE NEGATIVE REGULAR HYPER NO NO 1.65 NO
GOPIKA 29 F MNG MOBILE NEGATIVE REGULAR HYPO NO NO 2.8 YES
JAYA 61 F SNT FIXED POSITIVE IRREGULAR HYPO YES NO 1.5 YES
VARALAKSHMI 24 F SNT MOBILE NEGATIVE REGULAR HYPER NO NO 1.31 NO
MIRUNALINI 28 F MNG MOBILE NEGATIVE REGULAR HYPER YES NO 0.74 NO
MANGAYARKARASI 62 F SNT MOBILE NEGATIVE IRREGULAR HYPER NO NO 4.1 YES
KANCHANA 64 F DIFFUSE MOBILE NEGATIVE IRREGULAR HYPO NO NO 2.2 NO
MALA 27 F SNT MOBILE NEGATIVE REGULAR HYPER NO NO 0.69 NO
NAGESH 65 M MNG MOBILE NEGATIVE REGULAR HYPER NO NO 1.27 NO
AMIRTHA 34 F MNG MOBILE NEGATIVE REGULAR HYPER NO NO 1.19 NO
FARIDA 44 F SNT FIXED NEGATIVE REGULAR HYPER NO NO 0.76 YES
KHURSHID 67 F MNG MOBILE NEGATIVE REGULAR HYPER NO NO 1.65 NO
VIMALA 38 F MNG MOBILE NEGATIVE REGULAR HYPER NO NO 1.39 NO
LAKSHMI 68 F SNT MOBILE NEGATIVE IRREGULAR HYPER NO NO 0.75 NO
NARAYANAN 41 M MNG MOBILE NEGATIVE REGULAR HYPER NO NO 1.52 NO
VENKATESAN 55 M MNG MOBILE NEGATIVE REGULAR HYPER NO NO 3.1 NO
GEETHA 29 F DIFFUSE MOBILE NEGATIVE REGULAR HYPO YES NO 0.71 NO
JANANI 30 F SNT MOBILE NEGATIVE REGULAR HYPER NO NO 1.49 NO
GAYATHRI 27 F MNG MOBILE NEGATIVE REGULAR HYPER NO NO 1.47 NO
ANBARASI 50 F MNG MOBILE POSITIVE IRREGULAR HYPO YES YES 2.2 YES
GOMATHI 41 F MNG MOBILE NEGATIVE REGULAR HYPER NO NO 3.4 NO
RAZIYA BHANU 49 F SNT MOBILE NEGATIVE REGULAR HYPER NO NO 1.11 NO
JANNATH 51 F MNG FIXED NEGATIVE IRREGULAR HYPER NO NO 1.29 NO
VIJAYAKUMAR 64 M SNT MOBILE POSITIVE IRREGULAR HYPO NO NO 1.2 YES
MEENA 47 F MNG FIXED NEGATIVE REGULAR HYPO YES NO 0.81 YES
KALPANA 35 F MNG MOBILE NEGATIVE REGULAR HYPO NO NO 0.88 NO
KUMARI 62 F SNT MOBILE NEGATIVE REGULAR HYPO YES NO 1.37 NO
LATHA 65 F SNT MOBILE NEGATIVE IRREGULAR HYPER NO NO 2.4 YES
JEEVITHA 39 F DIFFUSE MOBILE NEGATIVE REGULAR HYPER NO NO 0.54 NO
MURUGAN 40 M MNG MOBILE NEGATIVE REGULAR HYPER NO NO 1.49 NO
SUBBALAKSHMI 61 F SNT FIXED NEGATIVE IRREGULAR HYPER NO NO 2.3 YES
VANITHA 61 F SNT FIXED NEGATIVE IRREGULAR HYPO NO NO 3.8 YES
VIJAYAPRIYA 62 F MNG MOBILE POSITIVE IRREGULAR HYPO YES YES 1.35 YES
MALAR 27 F MNG MOBILE NEGATIVE REGULAR HYPER NO NO 1.38 NO
PREM 31 M MNG MOBILE NEGATIVE REGULAR HYPER NO NO 0.61 NO
VASANTH 37 M MNG MOBILE NEGATIVE REGULAR HYPER NO NO 3.4 NO
RENUKA 44 F SNT MOBILE NEGATIVE REGULAR HYPO NO NO 2.8 NO
SUBHASHINI 63 F SNT MOBILE NEGATIVE IRREGULAR HYPER NO NO 1.44 NO
ANJALI 21 F MNG MOBILE NEGATIVE REGULAR HYPER YES NO 0.85 NO
AROKIAMARY 52 F MNG MOBILE NEGATIVE REGULAR HYPER NO NO 1.47 NO
ESWARI 56 F MNG MOBILE NEGATIVE REGULAR HYPER NO NO 1.67 NO
YOGAMAL 54 F MNG MOBILE NEGATIVE REGULAR HYPER NO NO 1.71 NO
SULOCHANA 62 F SNT MOBILE NEGATIVE IRREGULAR HYPER NO NO 2.6 NO
RAJARAJAN 47 M MNG FIXED NEGATIVE REGULAR HYPER NO NO 1.59 NO
VANI 61 F MNG MOBILE POSITIVE IRREGULAR HYPER YES NO 3.2 YES
MALATHI 31 F DIFFUSE MOBILE NEGATIVE REGULAR HYPER NO NO 0.77 NO
YASODHA 39 F MNG MOBILE NEGATIVE REGULAR HYPO NO NO 3.1 NO
SUBHA 40 F SNT MOBILE NEGATIVE REGULAR HYPER NO NO 0.64 NO
SENTHIL 40 M SNT FIXED NEGATIVE REGULAR HYPO NO NO 1.6 YES
TAMIL SELVI 66 F SNT FIXED NEGATIVE IRREGULAR HYPO NO NO 3.7 YES
SULTHANA 38 F MNG MOBILE NEGATIVE REGULAR HYPER NO NO 1.33 NO
NITHYA 24 F MNG MOBILE NEGATIVE REGULAR HYPER NO NO 1.44 NO
LATHA 41 F MNG MOBILE NEGATIVE REGULAR HYPER NO NO 4.4 NO
RAJAMANIKAM 69 M SNT MOBILE NEGATIVE IRREGULAR HYPO NO NO 0.58 NO
RAMYA 34 F MNG MOBILE NEGATIVE REGULAR HYPER NO NO 3.3 YES
SARADHA 50 F MNG MOBILE NEGATIVE REGULAR HYPER NO NO 1.32 NO
NASREEN 60 F MNG FIXED POSITIVE IRREGULAR HYPER YES NO 1.8 YES
RAMESH BABU 35 M MNG MOBILE NEGATIVE REGULAR HYPER NO NO 1.37 NO
ANUSYA 26 F DIFFUSE MOBILE NEGATIVE REGULAR HYPO NO NO 0.59 NO
LOGAPRIYA 31 F MNG MOBILE NEGATIVE REGULAR HYPER NO NO 1.55 NO
GAYATHRI 21 F MNG MOBILE NEGATIVE REGULAR HYPER NO NO 1.61 NO
SURESH 32 M MNG MOBILE NEGATIVE REGULAR HYPER NO NO 1.29 NO
SUNDAR 49 M MNG MOBILE NEGATIVE REGULAR HYPER NO NO 1.31 NO
KALAIVANI 33 F SNT MOBILE NEGATIVE REGULAR HYPER NO NO 0.78 NO
PADMA 60 F SNT FIXED POSITIVE IRREGULAR HYPO NO NO 2.1 YES
MONISHA 21 F DIFFUSE MOBILE NEGATIVE REGULAR HYPER NO NO 1.42 NO
KANNAGI 71 F MNG FIXED NEGATIVE REGULAR HYPER NO NO 2.7 NO
DIVYAMBIGAI 28 F MNG MOBILE NEGATIVE REGULAR HYPER NO NO 0.85 NO
CHITRA 60 F MNG FIXED NEGATIVE IRREGULAR HYPO NO NO 2.7 YES
ILAKIYA 34 F MNG MOBILE NEGATIVE REGULAR HYPER NO NO 1.37 NO
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